Literature DB >> 30352888

Long-term follow-up after switching from originator infliximab to its biosimilar CT-P13: the weight of nocebo effect.

Vincent Germain1,2, Marc Scherlinger1,2,3, Thomas Barnetche1, Thierry Schaeverbeke4,2.   

Abstract

Keywords:  DMARDs (biologic); anti-TNF-alpha; nocebo effect; patient attitude to health; rheumatoid arthritis; spondyloarthritis

Mesh：

Substances：

Year:  2018        PMID： 30352888     DOI： 10.1136/annrheumdis-2018-214374

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN： 0003-4967            Impact factor:   19.103


× No keyword cloud information.
  10 in total

1.  Open-label non-mandatory transitioning from originators to biosimilars in routine clinical care.

Authors:  Giuseppe Provenzano; Chiara Arcuri; Maria Concetta Miceli
Journal:  Clin Rheumatol       Date:  2020-08-10       Impact factor: 2.980

2.  A bio-what? Medical companions' perceptions towards biosimilars and information needs in rheumatology.

Authors:  Chiara Gasteiger; Urte Scholz; Keith J Petrie; Nicola Dalbeth
Journal:  Rheumatol Int       Date:  2021-10-27       Impact factor: 3.580

3.  Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study.

Authors:  Min-Chan Park; Hiroaki Matsuno; Jinseok Kim; Sung-Hwan Park; Sang-Heon Lee; Yong-Beom Park; Yun Jong Lee; Sang-Il Lee; Won Park; Dong Hyuk Sheen; Jung-Yoon Choe; Chan-Bum Choi; Seung-Jae Hong; Chang-Hee Suh; Shin-Seok Lee; Hoon-Suk Cha; Bin Yoo; Jin-Wuk Hur; Geun-Tae Kim; Wan-Hee Yoo; Han Joo Baek; Kichul Shin; Seung Cheol Shim; Hyung-In Yang; Hyun Ah Kim; Kyung-Su Park; In Ah Choi; Jisoo Lee; Masato Tomomitsu; Seonghye Shin; Jiyoon Lee; Yeong Wook Song
Journal:  Arthritis Res Ther       Date:  2019-05-21       Impact factor: 5.156

Review 4.  The Clinical Implications of Nocebo Effects for Biosimilar Therapy.

Authors:  Luana Colloca; Remo Panaccione; T Kevin Murphy
Journal:  Front Pharmacol       Date:  2019-11-29       Impact factor: 5.810

5.  Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry.

Authors:  Hyoun-Ah Kim; Eunyoung Lee; Sun-Kyung Lee; Yong-Beom Park; Young Nam Lee; Hee Jung Kang; Kichul Shin
Journal:  BioDrugs       Date:  2020-02       Impact factor: 5.807

6.  Influence of information provided prior to switching from Humira to biosimilar adalimumab on UK patients' satisfaction: a cross-sectional survey by patient organisations.

Authors:  Kayoko Kaneko; Daniel Prieto-Alhambra; Clare Jacklin; Ailsa Bosworth; Sally Dickinson; Sarah Berry; Helen McAteer; Peter C Taylor
Journal:  BMJ Open       Date:  2022-02-16       Impact factor: 2.692

Review 7.  Treatment journey in rheumatoid arthritis with biosimilars: from better access to good disease control through cost savings and prevention of nocebo effects.

Authors:  Josef S Smolen; Roberto Caporali; Thomas Doerner; Bruno Fautrel; Fabrizio Benedetti; Burkhard Pieper; Minjun Jang
Journal:  RMD Open       Date:  2021-06

Review 8.  Nonmedical Switching From Originators to Biosimilars: Does the Nocebo Effect Explain Treatment Failures and Adverse Events in Rheumatology and Gastroenterology?

Authors:  Roy Fleischmann; Vipul Jairath; Eduardo Mysler; Dave Nicholls; Paul Declerck
Journal:  Rheumatol Ther       Date:  2020-01-16

9.  Factors for starting biosimilar TNF inhibitors in patients with rheumatic diseases in the real world.

Authors:  Yoon-Kyoung Sung; Sun-Young Jung; Hyoungyoung Kim; Seongmi Choi; Seul Gi Im; Yu Sang Lee; Eun Jin Jang; Soo-Kyung Cho
Journal:  PLoS One       Date:  2020-01-24       Impact factor: 3.240

Review 10.  The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence.

Authors:  Brian G Feagan; Mona Marabani; Jashin J Wu; Freddy Faccin; Claire Spronk; Gilberto Castañeda-Hernández
Journal:  Adv Ther       Date:  2020-09-10       Impact factor: 3.845
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.